June 2010
Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3
Trade Publication
The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is effective, well tolerated and safe in treating CLI, which is considered the end-stage of peripheral artery disease (PAD). The highlights of the study and its significance to CLI patients are also discussed.


Related Articles

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld International;5/5/2010, Vol. 15 Issue 18, p5 

    The article deals with the preliminary Phase I data released by Pluristem Therapeutics Inc. for its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia in May 2010. Information on the Phase I trial results is presented. It discloses the company's negotiations for a Phase II...

  • PLURISTEM COMPLETES DOSING FOR FIRST PATIENTS IN CLI TRIAL.  // Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p6 

    The article reports on the completion by Pluristem Therapeutics Inc. of dosing of the first of three dosage groups of patients in Europe as part of its Phase I dose-escalating clinical trial of its placenta-derived cell therapy product PLX-PAD, for the treatment of critical limb ischemia (CLI)....

  • PLURISTEM GETS DSMB APPROVAL FOR PLX-PAD FINAL DOSE LEVEL.  // Biotech Business;Apr2010, Vol. 23 Issue 4, p6 

    The article announces the approval received by Pluristem Therapeutics Inc. of Haifa, Israel from the Safety Monitoring Board to advance to the highest and final dose level with its placenta-derived cell therapy (PLX-PAD) trial in Europe for the treatment of critical limb ischemia (CLI). Dr. Hans...

  • Pluristem files IND application to begin Phase I critical limb ischemia trial.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p10 

    The article reports on the investigational drug application filed by Pluristem Therapeutics to the U.S. Food and Drug Administration (FDA) in its aim to commence clinical trial with its placental-derived stromal cell product for the treatment of critical limb ischemia. The firm will begin its...

  • Financings Roundup.  // BioWorld Today;9/24/2008, Vol. 19 Issue 186, p5 

    The article reports that Pluristem Therapeutics Inc. of New York City has raised additional fundings of $1 million in September 2008. These new fundings will be used to support the development of their preclinical allogenic, placenta-derived cell therapy products. As reported, Pluristem sold...

  • Cell Therapy Treatment for Critical Limb Ischemia. Prather, William R. // Drug Discovery & Development;Nov/Dec2009, Vol. 12 Issue 10, p40 

    The article discusses the treatment of the peripheral artery disease (PAD) critical limb ischemia (CLI) through cell therapy. It is stated that clinical trials are conducted by Pluristem Therapeutics Inc. in the U.S. and Europe to identify the effectiveness of adherent stromal cell (ASC) in...

  • Pluristem's PLX-PAD Plans Boosted by $36M Offering. Boggs, Jennifer // BioWorld Today;1/28/2011, Vol. 22 Issue 19, p1 

    The article offers information on the public offering held by Pluristem Theraprutics Inc. to secure funding for its plans for a Phase II/III trial of placenta-derived cell therapy PLX-PAD for critical limb ischemia (CLI). The offering involved 11 million shares sold at 3.25 U.S. dollars each,...

  • CLINIC ROUNDUP.  // BioWorld Today;11/18/2009, Vol. 20 Issue 223, p8 

    This section offers news briefs on clinical trials. GlaxoSmithKline PLC, a partner of Anacor Pharmaceuticals Inc., has given six million U.S. dollars to Anacor as a milestone payment for the dosing of the first patient in a Phase I trial of AN3365 for hospital infections caused by Gram-negative...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics